Norwegian Gastrointestinal Cancer Group
Treatment of fixed, primarily non-resected rectal cancer. Recommendations from Norwegian Gastrointestinal Cancer Group
Abstract
In most cases (70%), fixed rectal cancers are primarily non-resectable, and of the ones that are resected, local recurrence will occur in 50-70%. The same trend, but less pronounced, is also seen for partly fixed or tethered tumours. High-dose irradiation (45-60 Gy) has been reported to yield resectability rates up to 70%, with 17% local recurrences and a 5-year disease-free survival of up to 60-70%. Combined chemotherapy and sequential radiation therapy, hyperthermia or addition of intra-operative radiotherapy, have shown promising results, but no randomized studies have been published comparing the different treatment modalities. Surgery should be performed 4-6 weeks after preoperative treatment. Resectability can only be determined by exploratory laparotomy and serious attempts to remove the tumour-bearing segment by anatomic dissection.
Source and rights
Published by Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1996. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- Norwegian Gastrointestinal Cancer Group
- Published
- 1996
- Applies to
- 🇳🇴 Norway
- Scope
- National
- Journal
- Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
- PubMed
- 8638268









